Medical Bulletin Board

New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients

Read Article

Findings from the CONFIDE Study show bowel urgency was the second most commonly reported symptom experienced by people with moderately-toseverely active ulcerative colitis, but many patients don’t feel comfortable reporting it to healthcare providers.

More than 60 percent of those patients who don’t feel comfortable reporting bowel urgency to their healthcare providers cite embarrassment as the top reason

Findings will be presented at the Advances in Inflammatory Bowel Diseases (AIBD) conference, taking place in Orlando and virtually December 9-11, 2021, with additional CONFIDE results presented at future congresses in 2022

INDIANAPOLIS, December 9, 2021 – Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show bowel urgency – defined as the sudden or immediate need for a bowel movement – is the second most commonly reported symptom suffered by study respondents living with moderately-to-severely active ulcerative colitis (UC), regardless of whether or not they were receiving an advanced therapy (biologic or novel oral therapy). In this study, only one in four healthcare providers perceived bowel urgency as one of the top three most reported symptoms by their patients.

The CONFIDE Study examines the experience of those living with moderately-to-severely active UC and Crohn’s disease and aims to advance the understanding of the burden, barriers and care experience of individuals with inflammatory bowel disease (IBD) and how they communicate with their healthcare providers. These U.S.specific data were collected from a cross-sectional survey of healthcare professionals and adults with moderately-to-severely active UC and Crohn’s disease in the U.S., Europe and Japan.

“Bowel urgency is a disruptive, often underreported symptom of ulcerative colitis and can be embarrassing and difficult for many people to talk about,” said David T. Rubin, M.D., professor of medicine, chief, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine and scientific advisor to the CONFIDE Study. “It is essential for those who care for people with inflammatory bowel disease to create an environment where they can have an open and trusting conversation about bowel urgency, especially considering this symptom is significantly associated with many patients’ perceived disease severity.”

In the CONFIDE Study, respondents living with moderately-to-severely active UC were asked which symptoms they experienced in the last month, as well as symptoms they had ever experienced, respectively. Diarrhea (experienced over the last month: 62.5%; have ever experienced: 74.0%), bowel urgency (experienced over the last month: 47.0%; have ever experienced: 61.5%) and increased stool frequency (experienced over the last month: 38.5%; have ever experienced: 57.5%) were reported as the top three symptoms suffered among respondents. 

 When asked to rank the top three symptoms they felt were most reported by their patients, three out of four healthcare providers (76.0%) did not identify bowel urgency, noting instead that the top three symptoms reported to them included diarrhea (73.5%), blood in stool (69.0%) and increased stool frequency (37.5%). 

Of the respondents living with moderatelyto-severely active UC who experienced bowel urgency, only two out of five (38.2%) felt completely comfortable reporting bowel urgency to their healthcare provider. For those who were not comfortable discussing bowel urgency with their healthcare provider, more than 60 percent reported that the top reason for not doing so was they were embarrassed to talk about it.

“The first findings from the CONFIDE Study shed light on an important conversation that may not be happening between healthcare providers and people living with ulcerative colitis. Many patients still feel embarrassed or struggle to explain symptoms like bowel urgency, a common experience that can take a toll on a person’s day-today life,” said Melodie Narain-Blackwell, founder, Color of Crohn’s and Chronic Illness.

Notably, when respondents with moderately-toseverely active UC were asked about their perceived disease severity, bowel urgency was significantly associated with those who considered their disease activity to be severe (62.9%) when compared with those that reported mild-to-moderately active disease (42.9%). Among the overall patient population surveyed, three-quarters (76.5%) of people were receiving advanced therapies (biologic or novel oral therapy), however; bowel urgency was still being currently experienced by almost one-half (46.4%) of respondents.

“One of the most important aspects of accurate diagnosis and treatment is to ensure that patients feel completely comfortable talking about their symptoms with their provider,” said Cem Kayhan, M.D., gastroenterology indications medical leader at Lilly. “These initial results from the CONFIDE Study help advance our understanding of the realworld experience of those living with and treating moderately-to-severely active ulcerative colitis, including those who are receiving advanced therapies and still experiencing bowel urgency. We look forward to sharing additional insights from the CONFIDE Study in the near future.” About The CONFIDE Study

The CONFIDE Study is a global, cross-sectional survey of healthcare professionals and people with moderately-to-severely active UC or Crohn’s disease in the U.S., Europe and Japan. The study looks at the experience and impact of symptoms and aims to provide further understanding of the burden, barriers and care experience of those living with these diseases. The global CONFIDE Study includes more than 1,600 adults living with UC or Crohn’s disease and more than 800 healthcare providers from the U.S., Europe and Japan. This specific U.S. disclosure included a total of 200 healthcare provider respondents and 200 adults living with ulcerative colitis. 

About the CONFIDE Scientific Advisory Panel*

The CONFIDE study was conducted by Adelphi Real World on behalf of Eli Lilly and Company, with expert guidance provided by some of the leading voices in UC research today, including (in alphabetical order):

Marla Dubinsky, Co-Director, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, U.S.

Toshifumi Hibi, Professor, Kitasato University, Kitasato Institute Hospital, Japan

Remo Panaccione, Professor of Medicine,

University of Calgary Cumming School of Medicine, Canada

David T. Rubin, Professor of Medicine, Chief, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, U.S.

Stefan Schreiber, Director of Internal Medicine,

University Hospital Schleswig-Holstein, Germany

Simon Travis, Professor of Clinical

Gastroenterology, Nuffield Department of Medicine, University of Oxford, U.K.

About Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory bowel disease that affects the colon. UC occurs when the immune system sends white blood cells into the lining of the intestines, where they produce chronic inflammation and ulcerations. There is an unmet need for additional treatment options for UC that provide meaningful symptom relief, including bowel urgency, and deliver sustained clinical remission.

About Eli Lilly and Company

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring lifechanging medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

To learn more about Lilly, please visit us at:  lilly.com and lilly.com/newsroom

*Members of the scientific advisory board serve as consultants and have received honoraria from Eli Lilly and Company.

P-LLY

Lilly Forward-Looking Statement

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the treatment of patients with ulcerative colitis and/or Crohn’s disease and reflects Lilly’s current beliefs and expectations. However, as with any disease treatment, there are substantial risks and uncertainties. Among other things, there can be no guarantee that future study results would be consistent with the study results reported. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Download Tables, Images & References

Medical Bulletin Board

Redhill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. Pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication

Read Article

Despite increasing resistance to, and suboptimal H. pylori eradication rates with, clarithromycin, a new study, published in Digestive Diseases and Sciences, indicates that over 80% of all prescriptions for H. pylori infection contain clarithromycin

In addition, this analysis highlighted a nearly 40% failure rate for clarithromycin-based triple therapies in treatment-naïve patients; Study also showed a more than 80% failure rate in CYP2C19 rapid metabolizers, accounting for approximately 30% of Americans

Talicia, an FDA-approved therapy, is intended for first-line H. pylori eradication therapy

RALEIGH, N.C. and TEL-AVIV, Israel, December 9, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the publication in the journal Digestive Diseases and Sciences of a new study entitled “Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data”, revealing concerning rates of widespread, physician-directed prescribing of clarithromycin-based regimens for patients with persistent H. pylori infection despite rising rates of antibiotic resistance and prior patient macrolide use.

“The failure rate of clarithromycin-based therapy is alarming enough on its own. More alarming still is that more than 80% of all prescriptions for H. pylori infection are clarithromycin-based therapies – despite clear ACG recommendations to avoid clarithromycin triple therapy in patients with any prior macrolide use or in regions where the resistance rate is known to be 15% or above  (or where resistance levels are not known),” said Dr. Colin W. Howden, MD, Professor Emeritus, Chief of the Division of Gastroenterology, University of Tennessee Health Science Center. “Such failure rates and resistance have not been seen with Talicia. Since it does not contain clarithromycin, Talicia can be prescribed first-line without having to be concerned about local clarithromycin resistance, prior macrolide use, or patient CYP2C19 status.”

This study assessed prescribing patterns and associated cure rates of physician-directed therapy for subjects with persistent H. pylori infection after participation in either of two Phase 3 clinical trials

(ERADICATE Hp and ERADICATE Hp2). The study also conducted CYP2C19 genotype analysis of subjects who were prescribed clarithromycinbased triple therapy. The most frequently selected treatments for physician-directed therapy from ERADICATE Hp and Hp2 were clarithromycinbased triple regimens (71.7%). Clarithromycinbased triple therapies across these studies showed eradication rates of approximately 60%, while rapid CYP2C19 metabolizers had eradication rates of less than 20%. This is clinically relevant because roughly one third of Americans have either rapid or ultra-rapid CYP2C19 metabolizer status[i]. Additionally, the study analyzed real world H. pylori retail prescription data, which revealed that the most frequently selected treatments for physician-directed therapy were clarithromycinbased triple regimens, accounting for more than 80% of prescriptions.

“This study highlights the need for a change in prescribing habits for H. pylori given rising resistance and the suboptimal eradication rates seen with clarithromycin-based regimens. This study demonstrated an approximately 60% eradication rate for clarithromycin-based therapies in treatment naïve patients[ii], which is consistent with recently published eradication rates[iii],” said Dr. June Almenoff, MD, Ph.D., RedHill’s Chief Medical Officer. “Conversely, efficacy data from the two Phase 3 studies demonstrated eradication rates of approximately 89% in the ERADICATE Hp mITT population and 90% in the ERADICATE Hp2 adherent population for Talicia in treatmentnaïve subjects, identified no primary or acquired resistance to rifabutin and found that cure rates were largely unaffected by CYP2C19 metabolic status.”

About Talicia®

Talicia® is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria seen with other antibiotics. The high rates of H. pylori resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based therapies and are a strong public health concern, as highlighted by the ACG, FDA and the World Health Organization (WHO) in recent years.

Talicia® is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019, Talicia® was approved by the U.S. FDA for the treatment of H. pylori infection in adults. In the pivotal Phase 3 study, Talicia® demonstrated 84% eradication of H. pylori infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p<0.0001). Minimal to zero resistance to rifabutin, a key component of Talicia®, was detected in RedHill’s pivotal Phase 3 study. Further, in an analysis of data from this study, it was observed that subjects who were confirmed adherent[iv] to their therapy had response rates of 90.3% in the Talicia® arm vs. 64.7% in the active comparator arm[v]. Talicia® is eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents which extend patent protection until 2034 with additional patents and applications pending and granted in various territories worldwide.

About H. pylori

H. pylori is a bacterial infection that affects approximately 35%[vi] of the U.S. population, with an estimated two million patients treated annually[vii]. Worldwide, more than 50% of the population has H. pylori infection, which is classified by the WHO as a Group 1 carcinogen. It remains the strongest known risk factor for gastric cancer[viii] and a major risk factor for peptic ulcer disease[ix] and gastric mucosa-associated lymphoid tissue (MALT) lymphoma[x]. More than 27,000 Americans are diagnosed with gastric cancer annually[xi]. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H. pylori-positive due to high resistance of H. pylori to antibiotics – especially clarithromycin – which is still commonly used in standard combination therapies[xii].

About RedHill Biopharma

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults[xiii], Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults[xiv], and Aemcolo® for the treatment of travelers’ diarrhea in adults[xv]. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (ABC294640), a firstin-class, oral SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), an oral serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (v) RHB-102, with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB106, an encapsulated bowel preparation.

More information about the company is available at:  www.redhillbio.com https://twitter.com/RedHillBio

About Talicia®

(omeprazole magnesium, amoxicillin and rifabutin)

INDICATION AND USAGE

Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillinclass antibacterial, and rifabutin, a rifamycin antibacterial , indicated for the treatment of Helicobacter pylori infection in adults.  To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

IMPORTANT SAFETY INFORMATION

Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycin.

Talicia is contraindicated in patients receiving rilpivirine-containing products.

Talicia is contraindicated in patients receiving delavirdine or voriconazole.

Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin.

Severe cutaneous adverse reactions (SCAR) (e.g. Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)) have been reported with rifabutin, amoxicillin, and omeprazole.  Additionally, drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rifabutin.

Acute Tubulointerstitial Nephritis has been Clostridioides difficile-associated diarrhea observed in patients taking PPIs and penicillins.

Clostridioides difficile-associated diarrhea observed in patients taking PPIs and penicillins.

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis.

Talicia may cause fetal harm. Talicia is not recommended for use in pregnancy. Talicia may reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.

Talicia should not be used in patients with hepatic impairment or severe renal impairment.

Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease.

The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.

To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at: 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Full prescribing information for Talicia is available at: Talicia.com

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Talicia®, and Aemcolo® and Movantik®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2021. All forwardlooking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Download Tables, Images & References

From the Pediatric Literature

Can We Predict Severity of Pancreatitis in Children?

Read Article

The incidence of acute pancreatitis (AP) in children has been increasing over time, and better modeling is needed to predict severe AP in this population. In this study, children with AP were recruited prospectively at a tertiary children’s hospital in the United States. AP was defined as occurring when a child had two of the following three criteria: abdominal pain consistent with AP, serum amylase or lipase level greater than 3 times the upper limit of normal, and imaging consistent with AP. A “derivation cohort” consisted of patients presenting with AP between 2016 and 2018 while a “validation cohort” consisted of patients diagnosed with AP between 2018 and 2019. Blood sampling was obtained within 48 hours of hospital admission for AP which then underwent analysis for the presence of multiple protein biomarkers (via the Luminex® assay), and C-reactive protein (CRP) levels were measured as well. Severity of pediatric pancreatitis was determined by pre-existing North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) guidelines. 

The derivation cohort consisted of 46 patients with AP and 20 control patients while the validation cohort consisted of 25 patients with AP and 10 control patients. No significant difference in age, sex, body mass index, etiology of AP, or AP severity was present between groups. Heatmap analysis demonstrated 48 biomarkers that were statistically significant when comparing patients with AP with controls. Specifically, Interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) levels were significantly higher in patients with severe AP in the derivation cohort compared to patients with mild AP and with controls. This testing was repeated in the validation cohort, and again, IL-6 and MCP-1 levels were significantly elevated in patients with severe AP compared to patients with mild AP as well as with controls.  CRP levels were significantly higher in both the derivation cohort and validation cohort for patients with severe AP compared to patients with mild AP and controls. The absolute neutrophil count, absolute lymphocyte count, and absolute monocyte count were significantly higher in the validation cohort for patients with severe AP compared to patients with mild AP and to control patients. Interestingly, ROC modeling demonstrated that blood urea nitrogen (BUN) levels were statistically correlated with severity of AP with a good area under the receiver operating characteristic (AUROC 0.72 [95% CI 0.57-0.87], P = .003), and BUN combined with CRP improved the model to a greater degree (AUROC 0.79 [95% CI 0.64-0.94]). Similar significant findings were noted when BUN was combined independently with IL-6 and MCP-1.

This study suggests that CRP levels are helpful in predicting severity in pediatric patients with acute recurrent pancreatitis which can then help guide therapy. IL-6 and MCP-1 are novel proteins that may prove to be useful as additional biomarkers for future studies.

Farrell P, Jones E, Hornung L, Thompson T, Patel J, Lin T, Nathan J, Vitale D, Habtezion A, Abu-El-Haija M. Cytokine profile elevations on admission can determine risks of severe acute pancreatitis in children. Journal of Pediatrics 2021; 238: 33-41.

Download Tables, Images & References

From the Pediatric Literature

Acid Suppression Use in Children with Laryngomalacia

Read Article

Laryngomalacia often is diagnosed in infants, and acid suppression therapy generally is prescribed due to concerns that acidic gastroesophageal reflux disease (GERD) can cause upper airway damage. Acid suppression therapy (via proton pump inhibitors or PPIs) often is used to prevent supraglottoplasty in patients with laryngomalacia. Since most cases of laryngomalacia resolve over time without surgical intervention, the authors of this study evaluated the effectiveness of acid suppression therapy to prevent potential supraglottoplasty. Patients with laryngomalacia were identified over a one-year period at a tertiary children’s hospital in the United States. These patients were evaluated for existing co-morbidities, severity of laryngomalacia, use of acid suppression medication, swallowing function (evaluated by both feeding evaluation and video swallow study), risk of hospitalization for respiratory disease, and risk of supraglottoplasty. 

A total of 236 patients were diagnosed with laryngomalacia during this study period, and 52% of patients had mild laryngomalacia with the remainder of the patients having either moderate-to-severe laryngomalacia or severity not being classified. It was noted that 55% of patients were on some type of acid suppression therapy (27% using H2-receptor antagonist therapy; 11% using PPI use; 17% using both), and no significant difference existed between acid suppression medication regimen and laryngomalacia severity. Most acid suppression therapy prescriptions were written by primary care physicians. No patient underwent pH-impedance testing for gastroesophageal reflux, and 10% of patients underwent esophagogastroduodenoscopy (for which only one patient was found to have microscopic esophagitis). A total of 40% of patients underwent a clinical feeding evaluation and 36% of patients had a video swallow study performed. Patients with moderate-to-severe laryngomalacia were more likely to undergo a clinical feeding evaluation or video swallow study. A clinical feeding evaluation led to a change in medical management in 72% of patients while a video swallow study led to a change in medical management in 61% of patients (including use of thickening agents or changing nipple flow). Supraglottoplasty occurred in 10% of these patients and repeat video swallow study testing showed an improvement in swallowing function in the patients that underwent surgery.

Univariate and multivariate analysis demonstrated that acid suppression use was significantly associated with an increased risk of hospitalization and an increased number of days in the hospital with respiratory disease (regardless of type of acid suppression therapy used). On the other hand, use of thickening agents significantly decreased the number of days that patients were hospitalized for respiratory disease. Of note, patients with an abnormal clinical swallow evaluation and/or video swallow study had no increase in hospitalizations, and no increased risk of hospitalization was noted regardless of laryngomalacia severity. It was noted that 40% of patients with severe laryngomalacia required surgery compared to 8% of patients with mild laryngomalacia and to 15% of patients with laryngomalacia not specified. However, acid suppression use was associated with an increased risk of progression to eventual supraglottoplasty regardless of laryngomalacia severity while thickening use was not associated with progression to this type of surgical intervention. Finally, acid suppression use was significantly associated with a more rapid progression to supraglottoplasty while thickener use was significantly associated with a increased time before performing supraglottoplasty regardless of laryngomalacia severity.  This is an extremely important study demonstrating that acid suppression therapy may be detrimental to outcomes in patients with laryngomalacia. The reason for this finding is not clear although effects on the gastric and pulmonary microbiome should be considered for further studies. Finally, thickening agent use in pediatric patients with laryngomalacia may be protective.

Duncan D, Larson K, Davidson K, Williams N, Liu E, Watters K, Rahbar R, Rosen R. Acid suppression does not improve laryngomalacia outcomes but treatment for oropharyngeal dysphagia might be protective. Journal of Pediatrics 2021; 238: 42-49.

Download Tables, Images & References

FROM THE LITERATURE

Branched-Chain Amino Acids in Cirrhosis with Sarcopenia

Read Article

To determine the effect of branched-chain amino acid (BCAA) supplementation on muscle mass in patients with cirrhosis and sarcopenia, a pilot, prospective, randomized and double-blind study of a cohort of 32 patients with cirrhosis and sarcopenia diagnosed by computed tomography scan who underwent a nutritional and physical activity intervention for 12 weeks was carried out. There was division into 2 groups (placebo 17 patients; BCAA 15 patients).  

Baseline characteristics were similar in both groups. After treatment, only the BCAA group presented a significant improvement in muscle mass (43.7 vs. 46 cm/m). A total of 17 patients (63%) presented improvement in muscle mass overall, which was more frequent in the BCAA group (83.3 vs. 46.7%). 

Regarding frailty, there was a significant improvement in Liver Frailty Index in the global cohort (N = 32), after the 12 weeks (4.2 vs. 3.9). This difference was significant in both groups: in the placebo group (4.2 vs. 3.8), and in the BCAA group (4.2 vs. 3.9). After treatment, the BCAA group had a higher increase in zinc levels than the placebo group (12.3 vs. 5.5). In addition, there was a trend for greater improvement of albumin levels in the BCAA group (0.19 vs. 0.04). 

It was concluded that BCAA supplementation improves muscle mass in cirrhotic patients with sarcopenia. 

Hernandez-Conde, M., Llop, E., GomezPimpollo, L., et al.  “Adding BranchChain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients with Sarcopenia: A Placebo-Controlled Trial.” American Journal of Gastroenterology, Vol. 116, November 2021, pp. 2241-2249.

Download Tables, Images & References

FROM THE LITERATURE

Treatment in Primary Biliary Cholangitis Refractory to Ursodeoxycholic Acid

Read Article

To assess the effectiveness and adverse effects of treatment of refractory primary biliary cholangitis (PBC), data from patients included in the ColHai Registry treated with OCA (obeticholic acid), fibrates, or both and were recorded during one year, as well as adverse effects and treatment discontinuation. 

A total of 86 patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. The OCA group had baseline significantly higher alkaline phosphatase (ALP) and lower platelets than fibrates. Both treatments significantly decreased ALP, GGT, and transaminases and improved GLOBE score. Albumin and immunoglobulin type M improved in the fibrates group. ALP decrease was higher under fibrates, whereas ALT decline was higher under OCA.

Although baseline transaminases and GGT were higher in patients with OCA plus fibrates, significant ALP, GGT, ALT and GLOBE score improvement were observed during triple therapy. Adverse events were reported in 14.7% of patients (21.3% OCA, 17.6% fenofibrate, 10.7% bezafibrate). This was mainly pruritus (10.1% with OCA). Discontinuation was more frequent in fenofibrate treatment, mainly because of intolerance or adverse events.  It was concluded that second-line therapy with OCA or fibrates improved hepatic biochemistry and the GLOBE score in PBC patients with suboptimal response to USDA. Simultaneous treatment with OCA and fibrates improved ALP as well.

Reig, A., Alvarez-Nevascues, C., Vergara, M., et al. “Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric, Observational Study.” American Journal of Gastroenterology, Vol. 116, November 2021, pp. 2250-2257.

Download Tables, Images & References

FROM THE LITERATURE

Statin Therapy for Prophylaxis of HCC in NASH with Cirrhosis

Read Article

To estimate the annual incidence of hepatocellular carcinoma (HCC) in patients with nonalcoholic steatohepatitis (NASH) with advanced liver fibrosis, and to determine the risk factors for development of HCC and the chemoprotective effect of statin use stratified by fibrosis stage, a retrospective study was carried out at two U.S. tertiary academic centers, including patients with NASH-related advanced liver fibrosis (bridging fibrosis – F3 and cirrhosis – F4), followed between July 2002 and June 2016. Patients were followed from the day of diagnosis to the day of last abdominal imaging, liver transplantation or HCC diagnosis. Multivariable Cox regression analysis was performed to evaluate the risk factors associated with HCC development, stratified by fibrosis stage.
A total of 1072 patients were included; 122 patients with F3 fibrosis and 950 patients with cirrhosis. No HCC was observed during 602 person-year follow up among F3 patients. Among patients with cirrhosis, HCC developed in 82 patients with an annual incidence rate of 1.90 per 100 person-years. Multivariable analysis in patients with cirrhosis demonstrated that HCC development was associated with male sex (HR 4.06), older age (HR 1.05), and CTP score (HR 1.38). Statin use was associated with a lower risk of developing HCC (HR 0.40). Each 365 increment in cumulative defined daily dose of statin use reduced the HCC risk by 23.6%.
The findings suggested that patients with NASH and bridging fibrosis have a low risk of HCC. Dose-dependent statin use reduced HCC risk significantly in patients with NASH cirrhosis.

Pinyopornpanish, K., Al-Yaman, W., Butler, R., et al. “Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis Cirrhosis.” American Journal of Gastroenterology, Vol. 116, November 2021, pp. 2258-2269.

Download Tables, Images & References

FROM THE LITERATURE

Treatment of Gastric Antral Vascular Ectasia

Read Article

Gastric antral vascular ectasia (GAVE) is typically treated by endoscopic thermal therapies (“watermelon stomach”). Endoscopic band ligation (EBL) had been reported with encouraging results and a comprehensive search of several databases was conducted (inception to May 2021), to identify studies reporting the use of EBL in treatment of GAVE. 

A random-effects model was used to calculate the pooled rates, I² values and 95% prediction intervals were calculated to assess the heterogeneity.

Ten studies (194 patients), were included in the final analysis. The pooled rate of treatment responders with EBL in GAVE was 81% and GAVE recurrence was 15.4%. The pooled mean number of treatment sessions required was 2.4 and the number of bands used to achieve eradication per patient was 15.1. The pooled mean difference of pre- to post-treatment hemoglobin was 1.5, pre- to post-treatment units of packed red cells transfused was 1.1, and pre- to post-treatment hospital length of stay was 0.5 days. The pooled rate of overall adverse effects was 15.9%. 

It was concluded that EBL demonstrated excellent clinical outcomes in the treatment of GAVE with minimal adverse events. Multicenter randomized control trials comparing EBL and other modalities as initial therapy are warranted.

Mohan, B., Toy, G., Kassab, L., et al. “Endoscopic Band Ligation in the Treatment of Gastric Antral Vascular Ectasia:  A Systematic Review and Meta-Analysis.” Gastrointestinal Endoscopy, 2021; Vol. 94, pp. 1021-1029.

Download Tables, Images & References

FROM THE LITERATURE

Proton Pump Inhibitor Therapy and Risk of All-Cause Mortality

Read Article

To determine the association between proton pump inhibitors (PPIs) use and mortality was evaluated by a prospective analysis of 440,840 UK residents and 13,154 deaths. The evaluation was carried out to determine the associations with multivariate Cox regression. 

After adjusting for confounders, such as health status and longstanding diseases, the regular use of PPIs was not associated with an increased risk of all-cause mortality and mortality due to neoplasms, circulatory system diseases, respiratory system diseases, digestive system diseases, external causes and other causes. 

It was concluded that regular use of PPIs was not associated with increased risk of all-cause and cause-specific mortality. 

He, Q., Xia, B., Meng, W., et al.  “No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality:  A PopulationBased Cohort of 0.44 Million Participants.” American Journal of Gastroenterology, Vol. 116, November 2021, pp. 2286-2291

Download Tables, Images & References

NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #219

High Output Ileostomies: Preventing Acute Kidney Injury

Read Article

Although most patients who undergo a total colectomy with a resulting end ileostomy do well in the post-operative period, as many as 16% to 50% of patients experience “high output.” High output ileostomies, defined as output >1500mL of effluent per day, can cause dehydration, electrolyte abnormalities, metabolic acidosis, and/or acute kidney injury (AKI), which may result in readmission and high health care costs. The best strategies to protect the kidneys involve preventing dehydration and subsequent injury from occurring in the first place. Preoperative patient education continuing through the postoperative and outpatient periods is of paramount importance, so patients are not only aware of normal ostomy output but are able to promptly recognize high output when it occurs, allowing for early treatment. Management includes fluid administration, pharmacologic interventions, and diet and beverage modification where appropriate.

INTRODUCTION

Over 300,000 colectomies are performed each year in the United States; approximately 130,000 of which are total colectomies resulting in an end ileostomy.1 The most common indications for a colectomy include toxic megacolon from Clostridium difficile infection, ulcerative colitis, diverticulitis, and colon cancer. Although most patients do well in the post-operative period, as many as 16% to 50% of patients experience “high output,” typically defined as greater than 1500mL of ostomy effluent in a 24-hour period.1,2

Some patients can maintain adequate hydration despite such high output, while others end up in an emergency department (ED) with dehydration, or worse, acute kidney injury (AKI) due to the severity of their dehydration, resulting in admission (Table 1). Not only are these ED visits or admissions an unpleasant inconvenience to patients, but they increase health care costs considerably. The purpose of this article is to provide an update on the earlier article: Bridges M, et al. High Output Ileostomies: The Stakes are Higher Than the Output,3 and to describe one institution’s attempts to mitigate this burden to patients and decrease coinciding health care costs.

What To Expect After a Colon Resection/Ostomy Creation

The colon avidly resorbs water and electrolytes, and thus, when removed, can result in difficulty maintaining hydration and electrolyte adequacy.2,4 It is of critical importance that a patient with a new ileostomy be educated on what is normal and abnormal in terms of both urine and ostomy output. This allows the patient, once they are discharged from the hospital, to recognize high output before AKI occurs. Normal ostomy output depends on the location of the stoma. For a patient with a colostomy, normal output is 200-600mL per day. In a new ileostomy, a patient can expect less than 1200-1500mL per day. This should decrease to 600-800mL once mature, which may take several weeks following surgery. A jejunostomy has the highest expected output due to its proximity and may put out as much as 6 liters per day.

Patients also need to be educated on normal urine output. Often the focus is on ostomy output alone, however, urine output is more a reflection of kidney function and adequate hydration. If the patient is not drinking enough, or not absorbing enough of what they drink, it often becomes the responsibility of the clinician to provide guidance and potential therapeutic interventions. Patients need to make at least 1200mL of urine each day to protect their kidneys; if they are a known kidney stone former, urine output should be higher at 1500mL/day. They should measure and record urine and ostomy output for 2 weeks after leaving the hospital, or until the first clinic visit and they are deemed “stable.” Note: patients will need to be given the tools to do this (stool hat or cylinder canister, male or female urinal – see Bridges citation).3

Causes of High Ileostomy Output

There are many disease processes that may cause or contribute to high ileostomy output. These include enteric infections such as Clostridium difficile and Salmonella, carcinoid syndrome, recurrent or active inflammatory bowel disease, a new medication initiation or withdrawal, and intraabdominal sepsis.3 High output may also be the result of “overflow” diarrhea from a stricture or obstructive process in the small bowel. Patients with less than 200 cm of small bowel with an end jejunostomy or ileostomy may suffer from short bowel syndrome.5,6 Furthermore, proximal stomas, small bowel fistulas, and poor quality of remaining bowel may mimic short bowel syndrome and result in high ostomy or fistula output.

There are also physiologic mechanisms that can play a role in high ileostomy output. Colectomies result in loss of absorptive surface area, but the remaining small intestine compensates by increasing the efficiency of fluid and electrolyte absorption through a process termed adaptation.2 Resection of 15-50 cm of terminal ileum increases daily ostomy volume by >300g/24 h when compared with controls with <15 cm removed.2 Hence, loop ileostomies typically have higher losses than end ileostomies (Figure 1). Additionally, terminal ileal resections decrease peptide YY secretion (whose function is to slow gastric emptying and inhibit small bowel motility), resulting in rapid transit.7 Small bowel transit is significantly faster in patients with greater lengths of ileal resections. Furthermore, extensive ileal resection (>100 cm) may also lead to bile salt deficiency resulting in steatorrhea.8 There have also been case reports of adrenal insufficiency presenting as large increases in ileostomy output.9,10 Acute adrenal insufficiency may present in response to stress and, when identified, is readily treatable with steroids. The mechanism by which this occurs is a result of glucocorticoid deficiency resulting in fasting hypoglycemia, muscle weakness, and gastrointestinal disturbances, including nausea, vomiting, diarrhea, and abdominal pain. Additionally, high circulating gastrin levels have been observed after major intestinal resections; although this is still poorly understood, it may be due to loss of enteric hormones such as GIP and VIP.11 This results in gastric acid hypersecretion, which may lead to impaired adaptation and nutrient absorption.5

There have been attempts to identify preoperative and intraoperative factors predictive of postoperative high output.12-14 In one institutional study, 36 out of 151 patients (23.8%) developed high output.12 Risk factors that were associated with high output were diabetes and total proctocolectomy, while patient age, gender, BMI, laxative use, total operative time, and blood transfusion were not statistically significant. In another retrospective review, also reporting a rate of high output around 23%, inflammatory bowel disease, diabetes mellitus, neoadjuvant chemoradiotherapy, total colectomy, and abdominal infections were found to be risk factors for high output.13 Another study examining predisposing factors for high ostomy output in patients with diverting loop ileostomies found American Society of Anesthesiologists (ASA) physical status classification (https://www. asahq.org/standards-and-guidelines/asa-physicalstatus- classification-system), elevated baseline creatinine, and open surgery to be risk factors for postoperative high output.14 Although there is no consensus regarding risk factors, physicians treating patients with any of these characteristics should be aware of the potential implications.

Readmission: Dehydration and/or Acute Kidney Injury (AKI)

Dehydration, with or without resulting AKI, is a common cause of hospital readmission in patients with an ileostomy.3 Ileostomy formation is strongly associated with subsequent kidney disease. Smith et al. found that the odds of developing an AKI is four times higher within 3 months of an ileostomy creation when compared to patients who have undergone a small bowel resection without ileostomy creation.15 Furthermore, odds of new-onset chronic kidney disease (CKD) were increased in the ileostomy group for both patients with previous AKI (OR~5) and without previous AKI (OR~2.5). Prevention and treatment are of upmost importance. Table 1 provides a summary of readmission rates by year for dehydration/ AKI of patients with an ileostomy reported in the literature.16-36

Intervention: Fluids and Diet

Common pitfalls and why they do not work:

  1. Instructing the patient to “just drink more.” However, this often increases ostomy losses and further dehydrates the patient.
  2. The patient may discover that if they drink less their stool output decreases, but unfortunately so does their urine output, further worsening kidney injury.
  3. There is also the patient who decides on their own that they should drink a lot since they have so much output, and again, drives their output further.
  4. Finally, there is the patient who is just not drinking enough, period.

The art of caring for these patients is to find that “sweet spot” of what, and how much, they can drink without making the ostomy output worse. There are some patients who will need IV fluids for a period of time, despite clinicians attempts at finding that “sweet spot.”

There is evidence to suggest that changes in diet may improve ostomy output. As the GI tract strives for isotonicity, if patients drink hypertonic fluids, water will be pulled into the small bowel lumen to dilute the higher osmotic fluid.6 Hypertonic fluids to avoid include fruit juices/drinks, regular sodas, sweet tea, maple or other syrups, ice cream, sherbet, and sweetened commercial liquid supplements such as Boost, Ensure, or store brand equivalents. Conversely, hypotonic solutions are the lesser of the evils, but still not good choices. These fluids pull sodium, and along with it, water into the small bowel lumen to increase the osmolarity. Examples include water, tea, coffee, alcohol, and diet drinks. Clinicians must also be careful to guide their patients away from sugar free and “diabetic” foods and beverages that may contain sugar alcohols (sorbitol, mannitol, xylitol, maltitol, isomalt, erythritol, lactitol, hydrogenated starch hydrolysates [HSH]) as they are very diarrheagenic. Oral rehydration solutions (ORS) are beneficial to some patients.6 These fluids do not decrease the quantity of output, but just result in better absorption of the ORS taken in, and hence, hydration of the patient. It is imperative that patients with new ileostomies receive some form of diet and specific hydration recommendations prior to discharge. Finally, there are some patients who just act like they have short bowel syndrome and it may be worthwhile to try a similar type diet, at least until the patient’s bowel adapts enough to absorb better. Make sure the patient understands they do not have short bowel, but that you are treating them as if they did for a period of time.

Intervention: Pharmacotherapy

When considering medications to prescribe to decrease ostomy output, it is important to first make sure you are not prescribing medications that will worsen the output. Liquid medications are commonly used for a variety of reasons, such as inability to swallow pills, dysphagia, and gastrostomy tubes. Despite the benefits of liquid medications, clinicians are often unaware of the possible sugar alcohols they can contain. Highly osmotic, highly fermentable, as well as cumulative, these drug additives can significantly contribute to ostomy output. While many clinicians are aware that liquid medications can contain sorbitol, a known laxative, many may not realize the other sugar alcohols used that can also contribute to diarrhea. See Table 2 for a select list of liquid medications containing sugar alcohols.

Because patients with an ileostomy have no colon, this also means that the need for fiber as a substrate for fermentation in the colon is of less importance,37 and that bile acid malabsorption and its sequalae is a non-issue. Therefore, cholestyramine, a medication indicated for bile acid malabsorption, has no role in the treatment of high ostomy output in those with an end ileostomy or jejunostomy. Fiber bulking agents may be utilized in stable, well-nourished patients to increase the viscosity of effluent if desired, which may improve quality of life in some patients. In patients with poor intake, this should be avoided as it may exacerbate water and electrolyte depletion and further decrease intake. It is important to note that these fiber bulking agents do not improve the hydration status of the patient.37 See Table 3 for other agents used to decrease stool volume in ileostomates with little efficacy. A better approach is to enlist an antidiarrheal agent to slow motility allowing more contact time with the mucosa for fluid to be absorbed. Clinical considerations for using antidiarrheal agents and antisecretory agents are available elsewhere.3 For one institution’s proposed escalation guidelines when enlisting antidiarrheals and antisecretory agents for high output, see Table 4.

Prevent and Protect

The best way to protect the kidneys is to prevent kidney injury from happening in the first place. There are several strategies in both the inpatient and outpatient settings to prevent dehydration and kidney injury. Patient education about what is normal for an ostomy and signs of dehydration should begin preoperatively and followed through in the postoperative inpatient and outpatient settings. Furthermore, emphasis should be placed on early and continued patient follow-up.

In the inpatient setting, ideally, IV fluids should be discontinued two days prior to anticipated discharge to mimic the home plan and oral intake and urine output should be monitored. Prior to discharge, the patient should demonstrate a urine output ≥ 1200mL/24 hours off IV fluids. In the postoperative setting, patients should be weighed at least two times per week initially to evaluate fluid status. Periodic labs should also be considered if appropriate. Basic metabolic panels and magnesium should be considered at 3 months, 6 months, and annually. If a patient is found to have hyponatremia, a 24-hour or random urinary sodium should be checked for sodium depletion as patients lose about 100mEq/mmol of sodium (2300mg sodium or 1 teaspoon of salt) per liter of effluent lost.38

Patients play an important role in preventing kidney injury and dehydration, especially once discharged from the hospital. Patients should be instructed to measure both their 24-hour urine and ostomy output for at least the first few weeks following surgery. If a patient will only measure one of these, emphasis should be placed on urine output. Patients need to be provided with 24-hour ileostomy and urine output targets, as well as daily oral volume intake targets. The goal ileostomy output should be < 1200-1500mL per day. An adequate 24-hour urine output is ≥1200mL, but this should be increased to 1500mL if a patient is prone to developing kidney stones. Furthermore, patients should try to drink at least 80 oz (2400mL) of fluid a day.2

Several institutions have implemented protocols aimed at patient education, follow-up, and/or treatment of dehydration, in attempts to decrease readmissions, all with varying levels of positive results.22,28,31,38-44 See Table 5 for a summary of published trials aimed at the prevent and protect strategy.

CONCLUSIONS

Dehydration, with or without resulting AKI, is common in patients who have recently undergone a total colectomy with an end or loop ileostomy, and often results in readmission. Strategies to prevent dehydration and educate patients on signs and symptoms of high output are imperative to reduce acute kidney injury, hospital readmissions, and decrease health care costs.

References

  1. Mulita F, Lotfollahzadeh S. Intestinal Stoma, in StatPearls. June 2021: Treasure Island (FL).
  2. Rowe KM, Schiller LR. Ileostomy diarrhea: Pathophysiology and management. Proc (Bayl Univ Med Cent). 2020 Jan 30;33(2):218-226.
  3. Bridges M, Nasser R, Parrish CR. High Output Ileostomies: the stakes are higher than the output. Pract Gastroenterol. 2019;Sept(9):20-33.
  4. Debongnie JC, Phillips SF. Capacity of the human colon to absorb fluid. Gastroenterology. 1978;74(4):698-703.
  5. Nightingale JM. Management of patients with a short bowel. World J Gastroenterol. 2001;7(6):741-51.
  6. Wall E. ORS: The Solutions to Optimize Hydration in Short Bowel Syndrome. Pract Gastroenterol. 2020;Mar(3):24-31.
  7. Bilchik AJ, Hines OJ, Adrian TE, et al. Early regional expression and secretion of peptide YY and enteroglucagon after massive resection of small bowel. J Am Coll Surg, 1995;180(4):417-26.
  8. Evans JA, Forcione DG, Friedman LS. Chapter 9 – Gastrointestinal Complications in the Postoperative Period, in Medical Management of the Surgical Patient (Third Edition), G.J. Merli and H.H. Weitz, Editors. W.B. Saunders: Philadelphia. 2008;275-347.
  9. Rai S, Hemingway D: Acute adrenal insufficiency presenting as high output ileostomy. Ann R Coll Surg Engl. 2003;85(2):105-6.
  10. Konda CS, Subramanian G, Gopalaratnam B. Adrenal Insufficiency Mimicking Gastrointestinal Disorder: A Case Report. Int J Sci Stud. 2015;3(8):204-206.
  11. DiBaise JK, Parrish CR. Short Bowel Syndrome in Adults – Part 1: Physiological Alterations and Clinical Consequences. Pract Gastroenterol. 2014;Aug(8):30-39.
  12. Takeda M, Takahashi H, Haraguchi N, et al. Factors predictive of high-output ileostomy: a retrospective single-center comparative study. Surg Today. 2019;49(6):482-487.
  13. Bai D, Li L, Shen Z, et al. Risk factors for developing high-output ileostomy in CRC patients: a retrospective study. BMC Surg. 2021;21(1):300.
  14. Assaf D, Hazzan D, Ben-Yaacov A, et al. Predisposing Factors for High Output Stoma in Patients with a Diverting Loop Ileostomy After Colorectal Surgeries. Ann Coloproctol. 2021;Aug 6:1-7.
  15. Smith SA, Ronksley PE, Tan Z, et al. New Ileostomy Formation and Subsequent Community-onset Acute and Chronic Kidney Disease: A Population-based Cohort Study. Ann Surg, 2021;274(2):352-358.
  16. Beck-Kaltenbach N, Voigt K, Rumstadt B. Renal impairment caused by temporary loop ileostomy. Int J Colorectal Dis. 2011;26(5):623-6.
  17. Hallbook O, Matthiessen P, Leinskold T, et al. Safety of the temporary loop ileostomy. Colorectal Dis. 2002;4(5):361-364.
  18. Åkesson O, Syk I, Lindmark G, et al. Morbidity related to defunctioning loop ileostomy in low anterior resection. Int J Colorectal Dis. 2012;27(12):1619-23.
  19. Gessler B, Haglind E, Angenete E. Loop ileostomies in colorectal cancer patients–morbidity and risk factors for nonreversal. J Surg Res. 2012;178(2):708-14.
  20. Hayden DM, Pinzon MC, Francescatti AB, et al. Hospital readmission for fluid and electrolyte abnormalities following ileostomy construction: preventable or unpredictable? J Gastrointest Surg, 2013;17(2):298-303.
  21. Messaris E, Sehgal R, Deiling S, et al. Dehydration is the most common indication for readmission after diverting ileostomy creation. Dis Colon Rectum. 2012;55(2):175-80.
  22. Nagle D, Pare T, Keenan E, et al. Ileostomy pathway virtually eliminates readmissions for dehydration in new ostomates. Dis Colon Rectum. 2012;55(12):1266-72.
  23. Paquette IM, Solan P, Rafferty JF, et al. Readmission for dehydration or renal failure after ileostomy creation. DisColon Rectum. 2013;56(8):974-9.
  24. Gessler B, Haglind E, Angenete E. A temporary loop ileostomy affects renal function. Int J Colorectal Dis. 2014;29(9):1131-5.
  25. Glasgow MA, Shields K, Vogel RI, et al. Postoperative readmissions following ileostomy formation among patients with a gynecologic malignancy. Gynecol Oncol. 2014;134(3):561-5.
  26. Phatak UR, Kao LS, You YN, et al. Impact of ileostomyrelated complications on the multidisciplinary treatment of rectal cancer. Ann Surg Oncol. 2014;21(2):507-12.
  27. Tyler JA, Fox JP, Dharmarajan S, et al. Acute health care resource utilization for ileostomy patients is higher than expected. Dis Colon Rectum. 2014;57(12):1412-20.
  28. Arenas Villafranca JJ, Lopez-Rodriguez C, Abiles J, et al. Protocol for the detection and nutritional management of high-output stomas. Nutr J. 2015 May 9;14:45.
  29. Orcutt ST, Li LT, Balentine CJ, et al. Ninety-day readmission after colorectal cancer surgery in a Veterans Affairs cohort. J Surg Res. 2016;201(2):370-7.
  30. Fish DR, Mancuso CA, Garcia-Aguilar JE, et al. Readmission After Ileostomy Creation: Retrospective Review of a Common and Significant Event. Ann Surg. 2017;265(2):379-387.
  31. Iqbal A, Raza A, Huang E, et al. Cost Effectiveness of a Novel Attempt to Reduce Readmission after Ileostomy Creation. JSLS. Jan-Mar 2017;21(1):e2016.00082.
  32. Li L, Lau KS, Ramanathan V, et al. Ileostomy creation in colorectal cancer surgery: risk of acute kidney injury and chronic kidney disease. J Surg Res. 2017;210:204-212.
  33. Justiniano CF, Temple LK, Swanger AA, et al. Readmissions with Dehydration After Ileostomy Creation: Rethinking Risk Factors. Dis Colon Rectum. 2018;61(11):1297-1305.
  34. Vergara-Fernandez O, Trejo-Avila M, Santes O, et al. Predictors of dehydration and acute renal failure in patients with diverting loop ileostomy creation after colorectal surgery. World J Clin Cases. 2019;7(14):1805-1813.
  35. Fielding A, Woods R, Moosvi SR, et al. Renal impairment after ileostomy formation: a frequent event with longterm consequences. Colorectal Dis. 2020;22(3):269-278.
  36. Loria A, Melucci A, Speranza J, et al. Acute Kidney Injury is a Common and Significant Complication Following Ileostomy Formation. Colorectal Dis. 2021 Sep 18.
  37. Wentworth B. Fiber and Ileostomies: Evidence to Support? Pract Gastroenterol. 2019;Nov(11):42-48.
  38. Nightingale JM. The medical management of intestinal failure: methods to reduce severity. Proc Nutr Soc. 2003;62(3):703-10.
  39. Hardiman KM, Reames CD, McLeod MC, et al: Patient autonomy-centered self-care checklist reduces hospital readmissions after ileostomy creation. Surgery. 2016;160(5):1302-1308.
  40. Shaffer VO, Owi T, Kumarusamy MA, et al. Decreasing Hospital Readmission in Ileostomy Patients: Results of Novel Pilot Program. J Am Coll Surg, 2017;224(4):425- 430.
  41. Migdanis A, Koukoulis G, Mamaloudis I, et al. Administration of an Oral Hydration Solution Prevents Electrolyte and Fluid Disturbances and Reduces Readmissions in Patients with a Diverting Ileostomy After Colorectal Surgery: A Prospective, Randomized, Controlled Trial. Dis Colon Rectum. 2018;61(7):840- 846.
  42. Grahn SW, Lowry AC, Osborne MC, et al. System-Wide Improvement for Transitions After Ileostomy Surgery: Can Intensive Monitoring of Protocol Compliance Decrease Readmissions? A Randomized Trial. Dis Colon Rectum. 2019;62(3):363-370.
  43. Gonella F, Valenti A, Massucco P, et al. A novel patientcentered protocol to reduce hospital readmissions for dehydration after ileostomy. Updates Surg. 2019;71(3):515-521.
  44. YV Loon, Poylin VY, Nagle D, et al. Effectiveness of the Ileostomy Pathway in Reducing Readmissions for Dehydration: Does It Stand the Test of Time? Dis Colon Rectum. 2020;63(8):1151-1155.

Download Tables, Images & References

Jojobet Girişmatbetcasibom güncel girişcasibomcasibomGrandpashabetgrandpashabetcasibom girişCasibomcasibommavibetcasibomMeritkingGrandpashabetCasibomgrandpashabetcasibombetpasjojobet girişjojobet güncel girişUltrabetmavibetmatbetcasibomdeneme bonusu veren sitelerJojobetJojobetMadridbetMadridbetgrandpashabetHoliganbet girişgrandpashabetgrandpashabet girişJojobetcasibomgrandpashabetjojobetcasinomilyoncasinomilyonultrabetultrabetgrandpashabet girişcasibom girişgrandpashabetholiganbetBetpasgrandpashabet güncel girişjojobet